Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injection Clear all
Completed Phase 1Phase 2 Interventional Results available

PK and Safety of SI-722 in IC/BPS

NCT04208087
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
SI-722, Placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Murrieta, California • The Villages, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation

NCT04510506
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas (AP)
Device
Lead sponsor
University of Virginia
Other
Eligibility
11 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

NCT03508921
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infections
Interventions
Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

NCT07645287
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
47
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Phase 1 Interventional

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416
View directory record Official record
Conditions
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
SIRPant-M, External-beam radiotherapy (XRT)
Biological · Radiation
Lead sponsor
SIRPant Immunotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

NCT05248893
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

NCT00000721
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

OTO-313 in Subjects With Unilateral Subjective Tinnitus

NCT04829214
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
OTO-313, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Fresno, California • Torrance, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Withdrawn Phase 2 Interventional

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

NCT01272258
View directory record Official record
Conditions
HIV
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

NCT05224258
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed 780G System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Little Rock, Arkansas • Fresno, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

NCT01450397
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
XIAFLEX
Biological
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
35 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

NCT05421013
View directory record Official record
Conditions
Facial isSCC
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

NCT07687784
View directory record Official record
Conditions
Iron Deficiency Anemia (IDA)
Interventions
Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®]
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Coral Gables, Florida • Melbourne, Florida • The Villages, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

NCT01038947
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Uricase-PEG 20
Biological
Lead sponsor
EnzymeRx
Industry
Eligibility
40 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT05099510
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Natrunix, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.

NCT04839497
View directory record Official record
Conditions
Amputation
Interventions
Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees
Combination Product
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

NCT00157339
View directory record Official record
Conditions
Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Human Insulin Inhalation Powder, injected insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
36
States / cities
Montgomery, Alabama • Burbank, California • Greenbrae, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 4:48 AM EDT
Not listed Not applicable Interventional

Electrical Stimulation After Botulinum Toxin Injections to the Upper Extremity

NCT04217187
View directory record Official record
Conditions
Stroke
Interventions
Neuromuscular Electrical Stimulation, Sham Electrical Stimulation
Device
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Phase 1 Interventional

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592
View directory record Official record
Conditions
Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
Interventions
vvDD-hIL-2-RG-1
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

OTO-313 in Subjects With Subjective Tinnitus

NCT03918109
View directory record Official record
Conditions
Tinnitus, Subjective
Interventions
OTO-313, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Sildenafil Increase Exercise Performance in Air Pollution?

NCT00808912
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Marywood University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

NCT01640730
View directory record Official record
Conditions
Stage IV NSCLC
Interventions
Kanglaite Injection
Drug
Lead sponsor
KangLaiTe USA
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 3 Interventional

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

NCT03617367
View directory record Official record
Conditions
Cervical Dystonia
Interventions
daxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 20, 2026, 4:48 AM EDT